Shares of Evotec SE (ETR:EVT - Get Free Report) rose 0.9% on Thursday . The stock traded as high as €8.10 ($8.44) and last traded at €8.00 ($8.33). Approximately 382,704 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 1,360,000 shares. The stock had previously closed at €7.93 ($8.26).
Evotec Price Performance
The business's 50 day moving average is €8.67 and its two-hundred day moving average is €7.57. The firm has a market capitalization of $1.42 billion, a PE ratio of -8.33, a P/E/G ratio of 0.98 and a beta of 1.05. The company has a debt-to-equity ratio of 46.81, a current ratio of 1.83 and a quick ratio of 2.97.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
